Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study
Journal of Diabetes Science and Technology (Ahead of Print)
Background: The majority of therapies have generally targeted fasting glucose control, and current mealtime insulin therapies have longer time action profiles than that of endogenously secreted insulin. The primary purpose of this study was to assess both glucose time-in-range (TIR: 70–180 mg/dL) and postprandial glucose excursions (PPGE) in 1–4 h using a real-time continuous glucose monitor (CGM) with Technosphere insulin (TI) versus insulin aspart in patients with type 1 diabetes (T1DM) on multiple daily injections (MDI).
Research Design and Methods: This pilot, investigator-led, collaborative, open-label, multicenter, clinical research trial enrolled 60 patients with T1DM with HbA1c levels ≥6.5% and ≤10%. Individuals were randomized to treatment with titrated TI (n = 26) or titrated insulin aspart (n = 34), stratified by baseline HbA1c levels (≤8% or >8%). All were required to wear a real-time CGM throughout the trial. All patients in the TI group were advised to take supplemental inhalations at 1 and 2 h after meals if indicated based on postprandial glucose (PPG) values. The coprimary outcomes were assessed both in the full intent-to-treat population and in those individuals randomized to TI who were compliant with supplemental doses ≥90% of the time (n = 15). The CGM data were analyzed using linear regression models.
Results: Overall, those treated with TI versus aspart achieved comparable TIR, but less time spent in hypoglycemia (<60 and <50 mg/dL, both P < 0.05). In the TI-compliant group (n = 15), TIR was significantly greater (62.5% ± 2.6% vs. 53.8% ± 1.7%, P = 0.009) and time in hyperglycemia >180 mg/dL was lower (34.2% ± 2.7% vs. 41.0% ± 1.7%, P = 0.045) as compared with the aspart group. PPG was also significantly lower in the TI cohort at 60 and 90 min postmeal, and PPGE were lower in the TI-compliant group as compared with the aspart group over 1–4-h postmeal (P < 0.05). In addition, there was weight gain in the aspart group compared with weight loss in the TI group (P = 0.006) despite higher prandial TI insulin dose.
Conclusions: We conclude that using TI appropriately at mealtimes with supplemental dosing improves prandial glucose (TIR and 1–4 h) control without any increase in time in hypoglycemia or weight gain in patients with T1DM on MDI. The study results support a larger study using a treat-to-target design to confirm these findings. Continue reading Afrezza: Medical Publications/Discussions
The power of a 4-unit dose of Afrezza: taken seconds after capturing the first screenshot, the time and glucose response says the rest! The 4 unit dosage has a 90 minute ‘active lifespan’ so no residual lows occur later on! #afrezza #T1D #Dexcom #reallife #simple pic.twitter.com/YnHmaiCSM7
— BeccaOnAfrezza (@BAfrezza) July 30, 2021
Thank you @novonordisk for your inadequate insulin. Not only was my blood glucose inadequate I had side effects. Thanks 2 my doctor I am now on a much better insulin.#Afrezza have non diabetic glucose levels and a lifetime best HbA1c of 5.8% I will never use ur analogues again! pic.twitter.com/6QaxAffE1T
— Brendan Hyland (@brendanphyland) June 11, 2021
I visited my endocrinologist today for the first time since starting on #Loop and my #A1c is 5.9 with only 2.9% of time spent below 75mg/dl. This is a huge improvement over my previous A1c's which were achieved mainly by being low >10% of the time. #WeAreNotWaiting #LoopKit pic.twitter.com/8IBsxWZlpK
— Alexander Getty (@gettyalex) June 11, 2021
Hard to believe I had dim sum for dinner yesterday and didn't break 129mg/dl. My routine of disabling #Loop for 4 hours and taking #Afrezza 10 minutes after eating with a follow-up dose an hour later worked flawlessly. I re-enabled Loop before falling asleep. #WeAreNotWaiting pic.twitter.com/4J6qL6lOlj
— Alexander Getty (@gettyalex) June 8, 2021
Eating, drinking and bowling with my boys at Lucky Strike in NYC. Afrezza keeping both of us in check. pic.twitter.com/spFseaC8Il
— Hillard Saveth (@HillardSaveth) June 4, 2021
Just finished pulmonary test after 3 years on #afrezza, no change in lung function from before I started on it and I have a cold. ?
— Laureen (@Reen910) April 10, 2021
AFREZZA is AMAZING!!! https://t.co/iNzhbQt3ZP@AfrezzaUS #afrezza #type1diabetic #diabetic #typeonediabetes #insulin #rapidacting #mannkind #mannkindcorp #betterlife #life #Diabetes #unitedhealthcare #bloodsugar #prescription #inhale #inhalableinsulin #travel #adventure #Bowtie
— Kevin Nicholas Gavit (@KevinGavit) February 14, 2021
Get Support from other Afrezza Users
If you are just starting to use Afrezza, you can post questions (such as titration or any other related issues) to the Afrezza User Facebook Group. People there are very helpful and responsive. Fudiabetes.org is a new forum run by a group of Afrezza-friendly people. Quite a few active Afrezza users post on that forum. Twitter is another platform where active Afrezza users post their results and share their experience quite frequently.